Zivo Bioscience Directors and CEO Rally in 11,709‑Share Buy, Sending Insider Confidence Skyward Amid Volatile Valuation Fluctuations

Insider Buying Spurs Optimism Amid Volatile Valuations

Zivo Bioscience Inc. has just seen a fresh influx of capital from its own board. On January 26, 2026, Cornell Alison A—an executive director—purchased 11,709 shares of Zivo’s common stock at $8.54 per share, bringing her post‑transaction holdings to 279,481 shares. The purchase came at a time when the company’s share price hovered near $9.75, a modest rise of 7.78 % over the week but still below the 52‑week low of $6.95. The trade’s timing aligns with a broader pattern of insider activity, including a simultaneous 11,709‑share buy by CEO John Bernard on the same day.

What Insider Buys Signal to Investors

Insider purchases are often interpreted as a vote of confidence in the company’s near‑term prospects. When executives step into the shoes of their own shareholders, they tacitly endorse the current valuation and the management team’s strategy. In Zivo’s case, the alignment between the CEO’s and the director’s buying suggests a unified belief that the company’s proprietary algal‑based platform could unlock value soon—particularly as Zivo positions itself within the growing natural personal‑care niche. Moreover, the transaction’s price of $8.54 is slightly below the current closing price of $9.75, indicating that insiders are willing to pay a premium for future upside.

Implications for the Broader Insider Activity

The January 26 purchase is part of a cluster of insider trades that began earlier in the month. Christopher D. Maggiore and Laith Yaldoe each bought 1,766 shares on January 14, while Yaldoe added another 2,777 shares in late December. These cumulative purchases have steadily increased insider ownership, reflecting a gradual accumulation strategy rather than a single speculative play. For investors, this pattern can be read as a “buy‑and‑hold” stance that mitigates short‑term volatility concerns. Still, the company’s negative price‑to‑earnings ratio of –3.68 and the absence of recent earnings guidance underscore that insider optimism is not yet matched by robust financial performance.

Assessing the Risk‑Reward Profile

From a risk perspective, Zivo remains a high‑volatility play. The share price’s recent decline to a 52‑week low, combined with a negative earnings trajectory, suggests that any upside will likely come from significant operational or product milestones. Conversely, the consistent buying by top executives can serve as a mitigating factor for investors wary of a potential “sell‑off” scenario. If the company can translate its algal‑culture technology into commercially viable products, insider confidence could translate into a sharp price rally—especially given the current market cap of $33.07 million and the substantial trading buzz (85 % communication intensity) noted around the filing.

Bottom Line for Investors

For those considering Zivo Bioscience, the recent insider buys are a positive signal but not a guarantee of imminent profitability. They should be weighed against the company’s current financial health, the broader consumer‑staples backdrop, and the technical signals that still suggest a bearish stance. If the company can deliver on its product pipeline and move toward sustainable earnings, the insider confidence could act as a catalyst for a breakout. Until then, investors might view Zivo as a high‑risk, high‑reward opportunity—best suited for those willing to accept significant volatility in exchange for potential long‑term upside.